SOUTH SAN FRANCISCO, Calif., April 23, 2023 (GLOBE NEWSWIRE) — UNITY Biotechnology, Inc. (“UNITY”) UBXa biotechnology company developing therapeutics to slow, halt or reverse the diseases of aging, announced today that on Monday, 24 am ET, it had partnered with retinal expert and Senior Clinical Advisor Robert B. Bhisitkul, MD, Ph.D. , the University of California San Francisco School of Medicine.

The live webcast is available in the “Investors and Media” section of our website, www.unitybiotechnology.comunder “Events & Presentations” or by clicking Here. A replay will be available two hours after the call closes and can be accessed in the Investors & Media section of our website under Events and Presentations.

About UNITY
UNITY is developing a new class of therapeutics to slow, halt or reverse the diseases of aging. UNITY’s current focus is on developing drugs to selectively eliminate or modulate senescent cells and thereby deliver transformative benefits in age-related ophthalmic and neurological diseases. For more information, see www.unitybiotechnology.com or continue to follow us Twitter And LinkedIn.

Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding the understanding of cellular senescence and the role it plays in the diseases of aging and UNITY’s potential to develop therapeutics to slow, halt or reverse diseases of aging, including ophthalmic and neurological diseases, the Potential for UNITY to successfully initiate and complete clinical trials of UBX1325 in DME, AMD and other ophthalmic conditions, the expected timing of UBX1325 clinical trial results and UNITY’s expectations regarding its liquidity adequacy. These statements involve significant known and unknown risks, uncertainties and other factors that could cause our actual results, levels of…